Navigation Links
High dose UDCA therapy does not improve overall liver histology in obesity related hepatitis
Date:4/16/2010

Vienna, Austria, Friday 16 April: Results of a German study presented today at the International Liver CongressTM 2010, the Annual Meeting of the European Association for the Study of Liver in Vienna, Austria, have shown that overall, treatment with high dose (23-28mg/kg/d) ursodeoxycholic acid (UDCA) is no more effective than placebo in the treatment of non-alcoholic steatohepatitis (NASH), the most advanced form of non-alcoholic liver disease associated with cirrhosis of the liver .

NASH is a serious development of non-alcoholic fatty liver disease (NAFLD), the most common persistent liver disorder in western countries and for which there is no proven medical therapy. Results from this study show that high dose UDCA a naturally occurring bile acid, historically used to treat gallstones is not superior to placebo therapy. Moderate histological and biochemical improvement was only observed in a subgroup of mildly overweight male patients.

Commenting on the study, Professor Fabio Marra of the EASL scientific committee said: "The use of UDCA is still considered controversial in non-alcoholic hepatitis, although previous research has suggested that the treatment may have some beneficial effects. The results of this study indicate that high dose UDCA is not superior to placebo except in a small subset of individuals. Nevertheless, the results do provide some interesting clinical pointers for clinicians in this field."

In the study, patients with histologically proven NASH (n=186, 147 of whom proceeded to treatment) were organised according to gender, body weight, liver biochemistry and histology and were randomised to receive either 23-28mg/kg/d UDCA or placebo for a period of 18 months.

Pre- and post-treatment liver biopsies from 139 patients were analysed, the primary evaluation criteria was an improvement in liver histology and secondary criteria were improvements in NASH-associated histological findings and liver function
'/>"/>

Contact: Isabelle Scali
media.easl2010@cohnwolfe.com
44-771-743-5103
European Association for the Study of the Liver
Source:Eurekalert

Page: 1 2

Related biology technology :

1. Seattle Facial Plastic Surgeon Among First In The Nation To Offer Ultherapy™
2. Cell Therapy Group Announces Expansion of Consultants Roster in Regenerative Medicine
3. Start of Phase I/II Gene Therapy Clinical Trial for Hemophilia B
4. Study: Medicare Covers Only Half the Cost of Administering Chemotherapy to Seniors with Cancer
5. California Stem Cell and ALS Therapy Development Institute Extend Their Collaboration to Advance Potential Stem Cell Assisted Therapy for ALS
6. ALS Therapy Development Institute and Oxford BioMedica Begin Second Phase of Collaboration to Develop Gene Therapies for Amyotrophic Lateral Sclerosis
7. Eribis Pharmaceuticals Receives Investment for Clinical Development of Novel Cardiovascular Therapy
8. Progenitor Cell Therapy Expands Manufacturing Operations
9. Stroke Therapy with Corkscrew Device Most Beneficial, Study Suggests
10. Women More Likely Than Men to Avoid Amputation After Minimally Invasive Therapy for Blocked Leg Arteries
11. Bioheart Makes Breakthrough in Critical Limb Ischemia Therapy with Stem Cells Obtained from Fat Tissue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... - Oncothyreon Inc.,(Nasdaq: ONTY ) (TSX: ... and,Trademark office has issued a patent for ... development. The newly issued patent, U.S. Patent,# ... matter of PX-867,and pharmaceutical preparations containing PX-867., ...
... 3SBio Inc.,(Nasdaq: SSRX ) ("3SBio" or ... focused on researching, developing, manufacturing and,marketing biopharmaceutical ... board of directors has approved a share ... 3SBio to purchase up to US$20 million ...
... Resubmit With New Data from Ongoing Studies, CAMBRIDGE, ... today announced the withdrawal of the European application,to extend ... elderly patients with acute myeloid leukemia (AML). This,application and ... by Bioenvision,Ltd. before the company was acquired by Genzyme ...
Cached Biology Technology:Oncothyreon announces issuance of patent for PX-867 2Oncothyreon announces issuance of patent for PX-867 33SBio Inc. Approves Share Repurchase Program 2Genzyme Withdraws Bioenvision's European Filing of Evoltra(R) in Elderly AML Patients 2Genzyme Withdraws Bioenvision's European Filing of Evoltra(R) in Elderly AML Patients 3
(Date:12/5/2014)... Calif. , Dec. 4, 2014 ... has boosted investments in new testing and inspection ... also given rise to a range of innovative ... the requirements of Generation Y, which is generally ... As a result, product development strategies of test ...
(Date:12/3/2014)... Dec. 2, 2014   Marvin Test Solutions ... test solutions for military, aerospace, and manufacturing organizations, ... its successful TS-900 PXI semiconductor test platform ... of high-end systems to customers at a fraction ... to traditional ATE. "Our semiconductor ...
(Date:11/21/2014)... 19, 2014  Earlier this year Donald Spector ... and one of the most prolific inventors in the ... transmitted from Smartphones to third party agencies. Spector envisioned ... one of the earliest known patents in this area. ... the military, child care, elder care and hospital applications. ...
Breaking Biology News(10 mins):Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4
... the possible inventory of molecules available to the ... research professor at Arizona State University, found that ... blazing fireball over California last year, contains organic ... findings suggest a far greater availability of extraterrestrial ...
... of Pharmaceutical Scientists (AAPS) WHAT: ... share the latest groundbreaking scientific discoveries and industry developments ... event will bring together more than 8,000 scientists, business ... initiatives underway aimed at improving global health through advances ...
... have discovered a new defense mechanism that the immune ... how a novel protein unexpectedly activates an immune response ... get rid of tumour cells. This research was done ... July 2013 in Nature Immunology ., 2. The immune ...
Cached Biology News:ASU scientists strike scientific gold with meteorite 2Novel mechanism discovered in first line of immune defense 2
For removal of the zona pellucida. Sterile, Mouse Embryo tested...
A substrate for all AChE-based EIA kits....
... Degranulation, the secretion of cytoplasmic granules, ... inflammatory response of leukocytes (e.g. basophils, ... addition to histamine, these secretory granules ... cytokines, chemokines, and many proteases (Hallgren, ...
... AGI provides both long and short-term enriched ... animals in both quarantine and non-quarantine settings ... are also available utilizing our state-of-the-art social ... is equipped with on site CDC quarantine ...
Biology Products: